Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16

Highlight

Based on the results of the ORION-16 trial, the following key highlights emerge regarding the use of inclisiran in the pediatric population:

1. Potent Efficacy: Inclisiran achieved a significant placebo-adjusted reduction of 28.5% in LDL cholesterol at day 330 in adolescents already on maximally tolerated lipid-lowering therapy.
2. Sustained Impact: The open-label extension (Part 2) demonstrated a mean LDL-C reduction of 33.7% from baseline at day 720, confirming the long-term durability of the siRNA approach.
3. Favorable Safety Profile: The safety and tolerability of inclisiran in adolescents were consistent with adult data, with no serious treatment-related adverse events and manageable, mild injection site reactions.
4. Simplified Adherence: The infrequent dosing schedule (twice yearly after the initial doses) provides a critical alternative for improving treatment compliance in adolescent patients.